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Summary Twenty-two children and adolescents who had received cisplatinum for the treatment of solid
tumours underwent audiometry to ascertain the extent of hearing damage. Five patients complained of hearing
difficulties, causing difficulty at school in one child. Hearing loss greater than 20 decibels occurred in four
patients at 1,000 Hz, seven at 2,000 Hz, 13 at 4,000 Hz and 21 at 8,000 Hz. Median hearing loss was greater at
higher frequencies (P<0.0001), and with increasing cumulative dose of cisplatinum. However, a 'plateau'
phenomenon was observed, with no apparent further deterioration in hearing loss at doses greater than
600 mg m-2. Two children who had received prior aural radiotherapy had severe hearing loss. Severe, mostly
asymptomatic, ototoxicity is common in children given cisplatinum. However, there is considerable inter-
patient variability in the hearing loss suffered.
Cisplatinum is a cytotoxic agent which is being increasingly
used in the management of paediatric solid tumours. It has
contributed to improved response rates in osteosarcoma
(Ettinger et al., 1981) and germ cell tumours (Pinkerton et
al., 1986). Recent studies have highlighted its efficacy in
certain resistant malignancies such as neuroblastoma, and its
apparently greater efficacy when used in higher dose regimens
(Ozols et al., 1983; Dini et al., 1987). However, its recognised
side-effects include nephrotoxicity, ototoxicity, myelosuppres-
sion, nausea and vomiting. Renal damage is the major dose-
limiting toxicity, but this has been reduced by improved
methods of drug administration. Ototoxicity has therefore
assumed greater importance, especially in younger children,
since it is generally thought to be irreversible, and therefore a
potentially serious long term handicap.
Several studies on cisplatinum ototoxicity, predominantly
in adults, have yielded different results in relation to its
incidence, severity and the occurrence of reversibility
(Aguilar-Markulis et al., 1981; Reddell et al., 1982; McHaney
et al., 1983; Moroso & Blair, 1983; Brock et al., 1987, 1988;
Ruiz et al., 1989). This may be due to variations in the
populations studied, different methods of assessing hearing
loss, and interactions with other ototoxic treatment.
Cisplatinum-induced damage appears to be mainly
confined to auditory function, with few reports of vestibular
toxicity, though the latter has seldom been specifically
sought. Symptoms of cisplatinum ototoxicity include
deafness, tinnitus, and otalgia (Moroso & Blair, 1983).
Although it can develop after several courses of treatment,
ototoxicity often appears early in treatment (Melamed et al.,
1985), and seems to be permanent in most patients (Aguilar-
Markulis et al., 1981; Reddell et al., 1982; McHaney et al.,
1983; Ruiz et al., 1989). Hearing loss tends to be bilateral,
cumulative with further treatment and more severe at higher
frequencies, although extension into the speech range can
occur (Aguilar-Markulis et al., 1981; Reddell et al., 1982;
McHaney et al., 1983; Ruiz et al., 1989). Previous or concur-
rent use of other ototoxic agents may increase toxicity by
more than simple algebraic summation (Aguilar-Markulis et
al., 1981). Hearing loss is greater with bolus administration
of cisplatinum, rather than infusion (Reddell et al., 1982).
A significant loss of outer hair cells in the lower turns of
the organ of Corti in the cochlea of Rhesus monkeys given
cisplatinum has been reported (Stadnicki et al., 1975), sugges-
ting a structural basis for ototoxicity, and similar findings
have been described in a 9-year-old boy with cisplatinum
ototoxicity (Strauss et al., 1983).
The present study aimed to determine the extent of hearing
loss in young people treated with cisplatinum, and to identify
those patients at greater risk of toxicity.
Correspondence: R. Skinner.
Received 2 May 1989; and in revised form 12 January 1990.
Patients and methods
Twenty-two patients (12 male) who had received cisplatinum
were studied (Table I). Their ages at start of treatment
ranged from seven to 19 years, mean 13 years. Eleven had
osteogenic sarcoma, five had primitive neuroectodermal
tumour (PNET), three had rhabdomyosarcoma, two neuro-
blastoma and one dysgerminoma. The median total dose of
cisplatinum received was 542 mg m-2 (range
312-1,072mgm-2) given over two to nine courses (median
four). The treatment regimens varied according to the child's
diagnosis, with individual cisplatinum dose ranging from 60
to 200 mg m-2 per course. The one patient who received
60 mg m-2 per course had end stage renal failure and was on
continuous ambulatory peritoneal dialysis, and therefore
received a low dose protocol. Patients with PNET or neuro-
blastoma received 200 mg m-2 (high dose) cisplatinum in five
doses of 40mg m-2 given on consecutive days as a I h
infusion in hypertonic saline without mannitol but with
3 Im-2 intravenous hydration for 7 days. Children with
osteogenic sarcoma usually received 100mgm2 per course
as a 24 h infusion with mannitol; those with rhabdomyosar-
coma were given 90mgm2 per course as an 8 h infusion,
again with mannitol. All patients received 3 1m-2 of in-
travenous fluids with calcium, magnesium and potassium
supplements before, during and after cisplatinum.
Eighteen patients received other potentially ototoxic drugs,
including gentamicin, vancomycin, netilmicin and
amphotericin B, for a range of from 1 to 90 days (median 10
days). Three patients received one to four courses of
bleomycin. Prior radiotherapy fields included both ears to
differing degrees in one patient, and one ear in another.
Audiometry was performed in sound proofed rooms by
qualified audiology technicians, using either a Kamplex AC4
or a Peters AP6 Clinical Diagnostic Audiometer, calibrated
to British Standards (BS2497), TDH39 headphones and
MX41AR cushions. The procedure followed was that des-
cribed by the British Society of Audiology (method A). All
patients were examined for evidence of middle ear disease.
A total of 79 audiograms were performed in the 22
patients. The first (baseline) audiogram was performed before
any cisplatinum was given in nine patients. Twenty-five
audiograms were carried out during the course of treatment.
After chemotherapy was completed, 45 audiograms (range
0-5, median 2) were performed during follow-up ranging up
to 62 months (median 15).
Significant hearing loss was taken as a deterioration in
hearing threshold of 20 decibels or greater at any frequency,
while recovery was judged to occur when the threshold im-
proved by 20 decibels or more in at least one frequency in at
least one ear in the follow up audiograms.
The 15 surviving patients and their parents were asked if
any hearing difficulty or tinnitus had been noted, and the
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Table I Patient and treatment details
No. ofaudiograns
Total dose Other ototoxic (timing relative to
Age cisplatinum treatment treatment)
(years) Sex Diagnosis (mgm-2) (days) Pre Intra Post
7 M Rhabdo 312 60 0 0 5
8 F PNET 578 10 1 1 2
9 M Rhabdo 360 45 0 1 3
10 M Neuro 620 58 1 1 2
10 F Rhabdo 436 16 0 0 3
10 F Osteo 360 9 0 0 2
11 F Osteo 596 4 0 1 3
11 F Osteo 590 10 0 0 2
11 F Osteo 388 30 0 0 2
12 M Osteo 564 8 1 1 2
13 M Neuro 1000 0 1 3 1
13 M Osteo 716 90 1 1 1
13 F Dysgerm 495 11 0 6 3
14 M PNET 576 0 1 2 2
15 F PNET 478 18 1 2 0
15 M Osteo 373 5 0 1 2
15 M Osteo 1072 0 0 2 1
17 M Osteo 521 15 0 1 1
17 F Osteo 617 1 0 1 2
18 M PNET 583 10 1 1 1
18 M PNET 400 0 1 0 2
19 F Osteo 414 17 0 0 3
Ageisageattreatmentwithcisplatinum. Dysgerm,dysgerminoma; Neuro,neuroblastoma;
Osteo, osteosarcoma; PNET, primitive neuroectodermal tumour; Rhabdo,
rhabdomyosarcoma. Other potentially ototoxic supportive treatment included amphotericin
B, gentamicin, netilmicin and vancomycin.
school teachers (of those still at school) asked whether any
hearing problems had been apparent.
Statistical analysis was performed on results from frequen-
cies of 1,000 Hz and greater. The maximum hearing loss at
each frequency in each patient (out of all their audiograms)
in right and left ears was compared using the Wilcoxin signed
rank test, and the mean (maximum loss in right ear plus that
in the left, divided by two) was used for further analysis.
Hearing loss at the different frequencies was compared by
means of the Friedman test and Tukey comparison, and
between patient groups by the Kruskall-Wallis test. The
effect of other variables on the hearing loss was assessed by
the Spearman rank correlation coefficient. Using the grading
system for ototoxicity (see Table III) proposed by Brock et
al. (1988), the severity of hearing loss in those patients
reporting hearing difficulties was compared with that in
asymptomatic patients by Fisher's exact test, two-tailed, com-
paring grades 0 and 1 with grades 2, 3 and 4.
Table n Hearing loss in the 22 patients
Frequency (Hz)
1,000 2,000 4,000 8,000
Hearing loss (dB)
Median 12.5 10.0 31.25 70.0
Range 2.5-32.5 0-62.5 7.5-95.0 17.5-95.0
Number (%) of
patients with hearing
loss of
>20 4 (18%) 7 (32%) 13 (59%) 21 (95%)
,60 0 (0%) 1 (5%) 5 (23%) 14 (64%)
70 -
Results
60
-
All nine children tested before therapy had a normal audio-
gram. The initial audiogram was performed during treatment
in a further six patients and was normal. There was no
significant difference in hearing loss between right and left
ears at any frequency in the group as a whole. The median
hearing loss in the group at the end of treatment was greater
at higher frequencies with significant differences between all
frequencies tested (F = 91.92; P<0.0001) except between
1,000 and 2,000 Hz (Table II). Correspondingly, the number
of patients who had significant hearing loss rose with increas-
ing frequency, as shown in Table II, for losses above 20 and
above 60 decibels. No evidence of serous otitis media was
found in any patient.
Figure I shows that the hearing loss increased and
extended to lower frequencies with increasing cumulative
doses of cisplatinum. However, a 'plateau' phenomenon was
observed with no further deterioration after 600 mg m2 in
most cases. This was most noticeable at 4,000 and 8,000 Hz
(see Figure 2). In contrast, there was no difference between
hearing loss in patients treated with different durations of
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Figure 1 Median hearing loss for each frequency with increasing
doses of cisplatinum, showing increasing loss with dose up to
600 mgm-2, and extension to lower frequencies. The pre-treatment
results (E) are based on nine audiograms, 1-200mg m2 (*) on
eight, 201-400mgm-2 (E) on 16, 401-600mgm-2 on (O) on 11,
and 601-1,100mgmr-2 (x) on seven.
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Figure 2 Median hearing loss at 8,000 Hz with increasing doses of
cisplatinum, showing 'plateau' phenomenon above 600mgm-2.
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other potentially ototoxic supportive treatment, comparing
1-10, 11-20 and 21-100 days of such treatment. There was
no significant correlation between maximum hearing loss in
each patient and the number of days of other potentially
ototoxic treatment received, the number of courses or the
total dose of cisplatinum given, or the age at start of treat-
ment. The three patients receiving bleomycin did not suffer
from severe ototoxicity. There was no significant difference in
hearing loss between the different disease groups.
The two patients who received radiotherapy to the ear
suffered severe hearing loss, especially at higher frequencies.
In one patient the irradiated ear was damaged more than the
contralateral ear at lower, but not at higher, frequencies.
Figure 3 shows the serial audiograms of this patient, illus-
trating these points, and also showing greater hearing losses
with increasing cisplatinum dose. Excluding these two
patients and also the patient with renal failure from the
statistical analysis made no difference to the overall results.
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Fiu 3 Serial audiograms showing progressive increase in hearing loss, and extension into lower frequencies, during cisplatinum
treatment in a patient with PNET, who also received prior radiotherapy involving his right ear...., pre-treatment; -, after 260 mg; ---,
after 510mg; . , after 760mg.
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Figure 4 Partial recovery in hearing loss after cessation of cisplatinum treatment
post-treatment; , 3 months post-treatment; - I year post-treatment.
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Table III Comparison between Great Ormond Street (Brock, personal
communication) and Newcastle series in the severity of hearing loss in
children after cisplatinum therapy.
Brock's cisplatinum ototoxicity grade OreotN
(Brock et al., 1988) SOreeto n ewasl
patients patients
Bilateral hearing (n = 29) (n = 22)
Grade Designation loss of % %
0 None <40dB at all 38 27
frequencies
I Mild >40dB at 8,000 Hz 14 32
2 Moderate > 40 dB at 4,000 Hz 24 32
3 Marked > 40dB at 2,000 Hz 21 9
4 Severe > 40dB atl,OOOHz 3 0
and below
Seven patients had audiometry at the end of treatment,
and also during follow up for at least one year. Of these, two
showed some recovery of hearing, with improvements of
20-35 dB noted at 8,000 Hz. Figure 4 shows serial audio-
grams of one of these patients.
Of the 15 survivors, four complained of slight and one of
moderate difficulty with hearing. School difficulties had been
noted with this latter child, but these had been relatively
easily managed in his normal class. He had been given a trial
with hearing aids, but these had been of no benefit. Four
patients complained of tinnitus. There was no difference in
the distribution of ototoxicity grading between those patients
with and those without symptoms (P = 0.19).
Discussion
Cisplatinum induced ototoxicity was first reported by Hill et
al. (1972). Subsequently, many studies have defined its
incidence and severity in adults, although less work has been
done in children. The overall incidence of hearing loss, as
determined by audiometry, in a review of eight studies
(mostly in adults) was 69% (though with a very wide range
from 11 to 91%), and that of tinnitus 7% (range 2-36%),
although it was often transient (Moroso & Blair, 1983).
However, in many adult studies of cisplatinum, the
incidence of ototoxicity is low. In contrast, in children receiv-
ing standard dose cisplatinum at three-weekly intervals in
one study, bilateral cumulative high frequency hearing loss
occurred in 88%, and the authors postulated that this high
incidence might be related to comparative immaturity of the
inner ear in younger patients (McHaney et al., 1983). The
loss was inversely related to age for any given cisplatinum
dose or frequency assessed. No recovery of function was
noted in nine children followed up montly for up to 15
months after stopping treatment. More recently, Brock has
confirmed that moderate or severe hearing loss occurs in over
50% of young patients given cisplatinum, warranting the use
of high frequency hearing aids in about a third of treated
children (Brock et al., 1987). She has proposed a grading
system (Table III) for ototoxicity in children (Brock et al.,
1988).
The present study confirms that cisplatinum causes ototox-
icity, with hearing loss increasing at higher frequencies.
Indeed, significant hearing loss occurred in all but one of the
patients at 8,000 Hz. However, only five reported any
difficulty in hearing, and several children were asymptomatic
despite severe hearing loss. It is notable that there is no
relation between ototoxicity grading and the presence or
absence of symptoms of hearing loss.
In agreement with most previous studies, the severity of
hearing loss in individual children tended to increase with
higher cumulative doses of cisplatinum. Although this rela-
tionship was also observed in the data from the group as a
whole (see Figure 1), no direct correlation between dose and
hearing loss was observed; this was probably largely due to
considerable interpatient variability.
The presence of a 'plateau' phenomenon is obviously of
considerable clinical importance. It has rarely been reported
previously (McHaney et al., 1983; Ruiz et al., 1989),
although recently Kopelman et al. (1988) have commented
on the implications, both for treatment and for understan-
ding the pathogenesis of cisplatinum-induced ototoxicity.
Although the use of differing periods of other potentially
ototoxic drugs did not appear to influence hearing loss in this
study, the use of aminoglycosides has been reported to cause
increased nephrototoxicity in humans receiving cisplatinum
(Salem et al., 1982), and ototoxicity in guinea pigs
(Schweitzer et al., 1984).
In agreement with Brock et al. (1987), though in contrast
to other studies (McHaney et al., 1983; Ruiz et al., 1989), no
correlation was observed between the patient's age at treat-
ment and the degree of hearing loss suffered.
Using Brock's classification (Brock et al., 1988), we have
graded the 22 patients in the present study, and compared
them with 29 patients receiving conventional dose cis-
platinum that she has studied (Brock, personal communica-
tion), as shown in Table III. There is no significant difference
in the distribution of ototoxicity grading between the 22
Newcastle patients and Brock's group (x2 = 4.3, d.f. = 3,
P> 0.05).
It is interesting to compare our group of patients with that
studied by Brock. Our patients were considerably older and
most had osteosarcoma, PNET or rhabdomyosarcoma, in
contrast to the younger patients with neuroblastoma and
germ cell tumour studied in Brock's group. In our group a
difference of 20 decibels between audiograms could be con-
sidered significant, whereas in young patients one would only
take a difference of about 40 decibels as unequivocal evidence
of a change in hearing threshold.
Our older group of children already had established lan-
guage skills by the time of diagnosis, and cisplatinum ototox-
icity would have had a less devastating effect on them, in
contrast to Brock's youngest patients, most of whom would
still be at an active stage in language acquisition. Severe
hearing loss at such an early age, especially when present at
lower frequencies, cannot be compensated for, in contrast to
the situation in older children, who appear to have con-
siderable ability to adapt and mask deafness. We believe,
however, that even these older children should undergo
regular audiometry during cisplatinum treatment to detect
subclinical hearing losses, since further damage may cause
severe loss at the lower frequencies which are of major
importance for speech.
The severe nature of the hearing loss in the two patients
who had received prior aural radiotherapy is in agreement
with previous experience (Mahoney et al., 1983; Walker et
al., 1989). This is of particular relevance in children with
brain tumours, where radiotherapy and cisplatinum treat-
ment are important components of management, as well as in
patients with other tumours in the head and neck region.
However, it is not known whether the combination of cisp-
latinum followed by aural radiotherapy is also associated
with such a high risk of ototoxicity.
Hearing loss in children due to cisplatinum has been stated
to be permanent (McHaney et al., 1983; Brock, personal
communication), even after follow-up of up to 5 years. We
have found evidence of some recovery of hearing on follow
up in two patients, using the criteria described earlier. How-
ever, this did not influence clinical management, and the one
surviving patient never complained of any hearing loss.
Ascertainment of the full extent of reversibility in hearing
loss awaits longer follow-up, which we are undertaking.
In conclusion, this study confirms that cisplatinum can
cause hearing loss in almost all patients, which is more severe
at higher frequencies. This hearing loss is greater with higher
cumulative doses ofcisplatinum, but appears to stabilise after
600 mg m2. Considerable interpatient variability is seen,
however. Ototoxicity tends to be more severe in patients whoOTOTOXICITY OF CISPLATINUM IN YOUNG 931
have previously received radiotherapy encompassing the ear.
Although many of the children studied were asymptomatic, it
cannot be confidently assumed that they will remain so with
increasing age. Regular audiometry will allow recognition of
asymptomatic hearing loss which may become important in
the future.
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